Advances in recent techniques for scientific data collection in the era of big data allow for the
systematic accumulation of large quantities of data at various data-capturing sites. Similarly …

Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …

Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of
anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …